Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2019 5
2020 4
2021 2
2022 7
2023 13
2024 13
2025 17
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Senescence in cancer.
Colucci M, Sarill M, Maddalena M, Valdata A, Troiani M, Massarotti M, Bolis M, Bressan S, Kohl A, Robesti D, Saponaro M, Shi Q, Song P, Brina D, Calì B, Alimonti A. Colucci M, et al. Among authors: robesti d. Cancer Cell. 2025 Jul 14;43(7):1204-1226. doi: 10.1016/j.ccell.2025.05.015. Epub 2025 Jun 12. Cancer Cell. 2025. PMID: 40513577 Free article. Review.
Dynamics of serum testosterone and biological aging in men: insights from Chinese, American, and British populations.
Huang W, Deng L, Wen Q, Zhang Z, Yue J, Zhang C, Zhou X, Jin Y, Hu D, Jiang Z, Manuel C, Daniele R, Aurora V, Zou X, Zhan Y, Chen L, Luo S, Sophia Z, Wei Q, Yang L, Dong B, Wang S, Qiu S. Huang W, et al. Among authors: daniele r. EClinicalMedicine. 2025 Apr 1;82:103178. doi: 10.1016/j.eclinm.2025.103178. eCollection 2025 Apr. EClinicalMedicine. 2025. PMID: 40235950 Free PMC article.
Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool.
Gandaglia G, Barletta F, Robesti D, Scuderi S, Rajwa P, Gomez Rivas J, Ibanez L, Soeterik TFW, Bianchi L, Afferi L, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler W, Marra G, Stabile A, Amparore D, Huebner NA, Giesen A, Joniau S, Schiavina R, Brunocilla E, Mattei A, Dal Moro F, Sierra JM, Porpiglia F, Picchio M, van den Bergh R, Shariat SF, Montorsi F, Briganti A. Gandaglia G, et al. Among authors: robesti d. Eur Urol Oncol. 2023 Dec;6(6):543-552. doi: 10.1016/j.euo.2023.05.003. Epub 2023 Jun 1. Eur Urol Oncol. 2023. PMID: 37270378
Reply by Authors.
Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, Karnes RJ, Heidenreich A, Pfister D, Kretschmer A, Buchner A, Stief C, Battaglia A, Joniau S, Van Poppel H, Osmonov D, Juenemann KP, Shariat S, Hiester A, Nini A, Albers P, Tilki D, Graefen M, Gill IS, Mottrie A, Galosi AB, Montorsi F, Briganti A. Fossati N, et al. Among authors: robesti d. J Urol. 2020 Aug;204(2):302. doi: 10.1097/JU.0000000000000800.03. Epub 2020 May 19. J Urol. 2020. PMID: 32427046 No abstract available.
Advances in laser pulse modulations.
Robesti D, Perri D, Bozzini G, Goumas IK, Ventimiglia E. Robesti D, et al. Curr Opin Urol. 2026 May 1;36(3):257-265. doi: 10.1097/MOU.0000000000001381. Epub 2026 Mar 6. Curr Opin Urol. 2026. PMID: 41823375 Review.
Addressing Uneven Treatment Discontinuation Rate in the Chemotherapy Arm of the EV-302 Phase 3 Randomized Clinical Trial: Implications for Outcome Interpretation.
Robesti D, Micheli F, Rai SN, Fallara G, Gallina A, Montorsi F, Briganti A, Fossati N, Grivas P, van der Heijden AG, Ploussard G, Malavaud B, Martini A. Robesti D, et al. Clin Genitourin Cancer. 2025 Dec;23(6):102423. doi: 10.1016/j.clgc.2025.102423. Epub 2025 Aug 28. Clin Genitourin Cancer. 2025. PMID: 41046201 Clinical Trial.
Subtype and Site Specific-Induced Metabolic Vulnerabilities in Prostate Cancer.
Mossa F, Robesti D, Sumankalai R, Corey E, Titus M, Kang Y, Zhang J, Briganti A, Montorsi F, Vellano CP, Marszalek JR, Frigo DE, Logothetis CJ, Gujral TS, Dondossola E. Mossa F, et al. Among authors: robesti d. Mol Cancer Res. 2023 Jan 3;21(1):51-61. doi: 10.1158/1541-7786.MCR-22-0250. Mol Cancer Res. 2023. PMID: 36112348 Free PMC article.
External Validation of Nomograms for the Identification of Pelvic Nodal Dissection Candidates Among Prostate Cancer Patients with Negative Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography.
Gandaglia G, Barletta F, Scuderi S, Scilipoti P, Rajwa P, Huebner NA, Gomez Rivas J, Ibanez L, Soeterik TFW, Bianchi L, Mattei A, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler WP, Marra G, Stabile A, Robesti D, Amparore D, Joniau S, Schiavina R, Sierra JM, Porpiglia F, Picchio M, Chiti A, Mottrie A, van den Bergh RCN, Shariat SF, Montorsi F, Briganti A. Gandaglia G, et al. Among authors: robesti d. Eur Urol Oncol. 2026 Feb;9(1):133-141. doi: 10.1016/j.euo.2025.01.004. Epub 2025 Jan 30. Eur Urol Oncol. 2026. PMID: 39890547
What to expect from the novel pulsed thulium:YAG laser? A systematic review of endourological applications.
Ventimiglia E, Robesti D, Bevilacqua L, Tondelli E, Oliva I, Orecchia L, Juliebø-Jones P, Pietropaolo A, De Coninck V, Esperto F, Tailly T, Ferretti S, Gauhar V, Somani B, Villa L, Keller EX, Salonia A, Traxer O, Kartalas Goumas I. Ventimiglia E, et al. Among authors: robesti d. World J Urol. 2023 Nov;41(11):3301-3308. doi: 10.1007/s00345-023-04580-z. Epub 2023 Sep 8. World J Urol. 2023. PMID: 37682286
Does the Accuracy of Prostate-specific Antigen Density in Identifying Clinically Significant Prostate Cancer Change with Prostate Volume?
Quarta L, Pellegrino F, Stabile A, Scilipoti P, Longoni M, Cannoletta D, Zaurito P, Santangelo A, Viti A, Cosenza A, Leni R, Pellegrino A, Barletta F, Scuderi S, Robesti D, Mazzone E, Brembilla G, Cobelli F, Montorsi F, Briganti A, Gandaglia G. Quarta L, et al. Among authors: robesti d. Eur Urol Focus. 2025 Dec 23:S2405-4569(25)00291-3. doi: 10.1016/j.euf.2025.10.005. Online ahead of print. Eur Urol Focus. 2025. PMID: 41444049
The added value of PSMA PET to nomograms in identifying optimal candidates for extended pelvic lymph node dissection in intermediate-risk prostate cancer patients.
Bauckneht M, Checcucci E, Lanfranchi F, Cisero E, Rizzo A, Scuderi S, Barletta F, Robesti D, Amparore D, Sterrantino A, Ortenzi M, DE Cillis S, DE Luca S, Rescigno P, Signori A, Pau V, Sambuceti G, Terrone C, Chiti A, Briganti A, Fiori C, Gandaglia G, Porpiglia F. Bauckneht M, et al. Among authors: robesti d. Minerva Urol Nephrol. 2025 Oct;77(5):639-646. doi: 10.23736/S2724-6051.25.06470-5. Minerva Urol Nephrol. 2025. PMID: 41128032
Trimodal treatment vs radical cystectomy for muscle-invasive bladder cancer: The neglected impact of informative censoring. A systematic review and meta-analysis.
Robesti D, Micheli F, Rai SN, Fallara G, Gallina A, Montorsi F, Briganti A, Fossati N, van der Heijden AG, Ploussard G, Malavaud B, Martini A. Robesti D, et al. Crit Rev Oncol Hematol. 2025 Oct;214:104815. doi: 10.1016/j.critrevonc.2025.104815. Epub 2025 Jun 20. Crit Rev Oncol Hematol. 2025. PMID: 40545069
Is Pulse Modulation the Future of Laser Technology in Endourology: Evidence from a Literature Review - Section of EAU Endourology.
Corsini C, Robesti D, Villa L, Montorsi F, Pietropaolo A, Panthier F, Sierra A, Juliebø-Jones P, Kwok JL, Tsaturyan A, Contreras P, Fossati N, Gallina A, Xavier Keller E, Knoll T, Kartalas Goumas I, Somani BK, Traxer O, Salonia A, Ventimiglia E. Corsini C, et al. Among authors: robesti d. Eur Urol Focus. 2025 Mar;11(2):347-355. doi: 10.1016/j.euf.2024.10.009. Epub 2024 Nov 13. Eur Urol Focus. 2025. PMID: 39542788
PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment.
Bianchi L, Ceci F, Balestrazzi E, Costa F, Droghetti M, Piazza P, Pissavini A, Presutti M, Farolfi A, Mei R, Castellucci P, Gandaglia G, Larcher A, Robesti D, Mottrie A, Briganti A, Morganti AG, Fanti S, Montorsi F, Schiavina R, Brunocilla E. Bianchi L, et al. Among authors: robesti d. Cancers (Basel). 2023 Mar 29;15(7):2027. doi: 10.3390/cancers15072027. Cancers (Basel). 2023. PMID: 37046687 Free PMC article.
Utility of MRI perilesional biopsy in prostate cancer: impact of the Prostate Imaging-Reporting and Data System and biopsy history.
Cannoletta D, Stabile A, Quarta L, Barletta F, Pellegrino F, Scuderi S, Porzi ME, Scilipoti P, Robesti D, Longoni M, Mazzone E, Brembilla G, De Cobelli F, Gandaglia G, Karnes JR, Roupret M, Montorsi F, Briganti A. Cannoletta D, et al. Among authors: robesti d. BJU Int. 2026 Feb;137(2):282-288. doi: 10.1111/bju.70027. Epub 2025 Oct 13. BJU Int. 2026. PMID: 41077924
Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation.
Nocera L, Fallara G, Raggi D, Belladelli F, Robesti D, Montorsi F, Karakiewicz PI, Malavaud B, Ploussard G, Necchi A, Martini A. Nocera L, et al. Among authors: robesti d. Front Oncol. 2022 Sep 5;12:955894. doi: 10.3389/fonc.2022.955894. eCollection 2022. Front Oncol. 2022. PMID: 36132135 Free PMC article.
Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis.
Fallara G, Belladelli F, Robesti D, Raggi D, Nocera L, Marandino L, Galsky MD, Montorsi F, Malavaud B, Ploussard G, Necchi A, Martini A. Fallara G, et al. Among authors: robesti d. Crit Rev Oncol Hematol. 2022 Nov;179:103801. doi: 10.1016/j.critrevonc.2022.103801. Epub 2022 Aug 27. Crit Rev Oncol Hematol. 2022. PMID: 36031173
Temperature profile during endourological laser activation: introducing the thermal safety distance concept.
Ventimiglia E, Robesti D, Keller EX, Corsini C, Folcia A, Fantin M, Candela L, Pozzi E, Sierra A, Pietropaolo A, Somani BK, Panthier F, Pauchard F, Goumas IK, Villa L, Montorsi F, Traxer O, Salonia A, Saccomandi P. Ventimiglia E, et al. Among authors: robesti d. World J Urol. 2024 Jul 29;42(1):453. doi: 10.1007/s00345-024-05162-3. World J Urol. 2024. PMID: 39073430
Is Active Surveillance an Option for the Management of Men with Low-grade Prostate Cancer and a Positive Family History? Results from a Large, Single-institution Series.
Leni R, Gandaglia G, Stabile A, Mazzone E, Pellegrino F, Scuderi S, Robesti D, Barletta F, Cirulli GO, Cucchiara V, Zaffuto E, Dehò F, Montorsi F, Briganti A. Leni R, et al. Among authors: robesti d. Eur Urol Oncol. 2023 Oct;6(5):493-500. doi: 10.1016/j.euo.2023.02.014. Epub 2023 Mar 31. Eur Urol Oncol. 2023. PMID: 37005213
The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials.
Robesti D, Nocera L, Belladelli F, Schultz JG, Fallara G, Marandino L, Raggi D, Montorsi F, Msaouel P, Necchi A, Martini A. Robesti D, et al. BJU Int. 2024 Feb;133(2):158-168. doi: 10.1111/bju.16121. Epub 2023 Jul 25. BJU Int. 2024. PMID: 37422731 Free PMC article.
Re: Kathia De Man, Nick Van Laeken, Vanessa Schelfhout, et al. 18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial. Eur Urol. 2022;82:501-509.
Montorsi F, Gandaglia G, Robesti D, Dehò F, Briganti A. Montorsi F, et al. Among authors: robesti d. Eur Urol. 2022 Nov;82(5):e143. doi: 10.1016/j.eururo.2022.07.035. Epub 2022 Aug 19. Eur Urol. 2022. PMID: 35989206 No abstract available.
Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study.
Gandaglia G, Mazzone E, Stabile A, Pellegrino A, Cucchiara V, Barletta F, Scuderi S, Robesti D, Leni R, Samanes Gajate AM, Picchio M, Gianolli L, Brembilla G, De Cobelli F, van Oosterom MN, van Leeuwen FWB, Montorsi F, Briganti A. Gandaglia G, et al. Among authors: robesti d. Eur Urol. 2022 Oct;82(4):411-418. doi: 10.1016/j.eururo.2022.06.002. Epub 2022 Jul 22. Eur Urol. 2022. PMID: 35879127 Free article. Clinical Trial.
Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer.
Pellegrino A, Gandaglia G, de Angelis M, Fallara G, Mazzone E, Stabile A, Pellegrino F, Robesti D, Leni R, Scuderi S, Cucchiara V, Cirulli GO, Barletta F, Montorsi F, Briganti A. Pellegrino A, et al. Among authors: robesti d. World J Urol. 2023 Aug;41(8):2069-2076. doi: 10.1007/s00345-023-04460-6. Epub 2023 Jun 16. World J Urol. 2023. PMID: 37326656
Understanding the Role of Ureteral Access Sheath in Preventing Post-Operative Infectious Complications in Stone Patients Treated with Ureteroscopy and Ho:YAG Laser Lithotripsy: Results from a Tertiary Care Referral Center.
Villa L, Dioni P, Candela L, Ventimiglia E, De Angelis M, Corsini C, Robesti D, Fantin M, D'Arma A, Proietti S, Giusti G, Kartalas Goumas I, Briganti A, Montorsi F, Salonia A. Villa L, et al. Among authors: robesti d. J Clin Med. 2023 Feb 12;12(4):1457. doi: 10.3390/jcm12041457. J Clin Med. 2023. PMID: 36835992 Free PMC article.
The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence.
Bianchi L, Ceci F, Costa F, Balestrazzi E, Droghetti M, Piazza P, Pissavini A, Mei R, Farolfi A, Castellucci P, Puliatti S, Larcher A, Gandaglia G, Robesti D, Mottrie A, Briganti A, Morganti AG, Fanti S, Montorsi F, Schiavina R, Brunocilla E. Bianchi L, et al. Among authors: robesti d. Cancers (Basel). 2022 Dec 30;15(1):247. doi: 10.3390/cancers15010247. Cancers (Basel). 2022. PMID: 36612242 Free PMC article.
The Impact of Second Opinion Expert Pathology Review in Patient Management at the Time of Transurethral Resection of the Bladder.
Robesti D, Moschini M, Pio Tenace N, Burgio G, Re C, Leni R, De Angelis M, Scilipoti P, Pellegrino F, Cannoletta D, Gandaglia G, Fossati N, Gallina A, Doglioni C, Colecchia M, Salonia A, Montorsi F, Briganti A, Lucianò R. Robesti D, et al. Eur Urol Focus. 2024 Dec;10(6):1043-1048. doi: 10.1016/j.euf.2024.06.007. Epub 2024 Jun 26. Eur Urol Focus. 2024. PMID: 38937195
Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
Pellegrino F, Stabile A, Sorce G, Quarta L, Robesti D, Cannoletta D, Cirulli G, Barletta F, Scuderi S, Mazzone E, de Angelis M, Brembilla G, De Cobelli F, Salonia A, Montorsi F, Briganti A, Gandaglia G. Pellegrino F, et al. Among authors: robesti d. Eur Urol Focus. 2024 Jul;10(4):634-640. doi: 10.1016/j.euf.2023.10.006. Epub 2023 Oct 19. Eur Urol Focus. 2024. PMID: 37865591
Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters.
Mazzone E, Gandaglia G, Robesti D, Rajwa P, Gomez Rivas J, Ibáñez L, Soeterik TFW, Bianchi L, Afferi L, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler WP, Amparore D, Huebner NA, Giesen A, Joniau S, Schiavina R, Brunocilla E, Mattei A, Dal Moro F, Moreno Sierra J, Porpiglia F, Picchio M, Chiti A, van den Bergh R, Shariat SF, Montorsi F, Briganti A. Mazzone E, et al. Among authors: robesti d. Eur Urol Oncol. 2024 Apr;7(2):231-240. doi: 10.1016/j.euo.2023.08.010. Epub 2023 Sep 9. Eur Urol Oncol. 2024. PMID: 37689506
Defining the optimal target-to-background ratio to identify positive lymph nodes in prostate cancer patients undergoing robot-assisted [99mTc]Tc-PSMA radioguided surgery: updated results and ad interim analyses of a prospective phase II study.
Quarta L, Mazzone E, Cannoletta D, Stabile A, Scuderi S, Barletta F, Cucchiara V, Nocera L, Pellegrino A, Robesti D, Leni R, Zaurito P, Brembilla G, De Cobelli F, Samanes Gajate AM, Picchio M, Chiti A, Montorsi F, Briganti A, Gandaglia G. Quarta L, et al. Among authors: robesti d. Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3789-3798. doi: 10.1007/s00259-024-06789-5. Epub 2024 Jun 11. Eur J Nucl Med Mol Imaging. 2024. PMID: 38861182 Free PMC article. Clinical Trial.
Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study.
Rajwa P, Robesti D, Chaloupka M, Zattoni F, Giesen A, Huebner NA, Krzywon A, Miszczyk M, Moll M, Stando R, Cisero E, Semko S, Checcucci E, Devos G, Apfelbeck M, Gatti C, Marra G, van den Bergh RCN, Goldner G, Rasul S, Ceci F, Dal Moro F, Porpiglia F, Gontero P, Bjartell A, Stief C, Heidenreich A, Joniau S, Briganti A, Shariat SF, Gandaglia G; EAU-Young Academic Urologists (YAU) Prostate Cancer Working Party. Rajwa P, et al. Among authors: robesti d. Eur Urol Oncol. 2024 Aug;7(4):721-734. doi: 10.1016/j.euo.2023.09.006. Epub 2023 Oct 14. Eur Urol Oncol. 2024. PMID: 37845121 Free article.
Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy.
Martini A, Fossati N, Karnes RJ, Boorjian SA, Boeri L, Bossi A, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Robesti D, Bartkowiak D, Böhmer D, Shariat SF, Goldner G, Battaglia A, Joniau S, Berghen C, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Wiegel T, Briganti A. Martini A, et al. Among authors: robesti d. Eur Urol Oncol. 2021 Apr;4(2):301-304. doi: 10.1016/j.euo.2019.11.003. Epub 2019 Dec 4. Eur Urol Oncol. 2021. PMID: 31810893 Clinical Trial.
Laser Energy Application in Endoscopic Kidney-Sparing Surgery for Upper Tract Urothelial Carcinoma: A Systematic Review of Oncological Outcomes and Surgical Complications.
Zorzi F, Scilipoti P, Moretto S, Gonzalez-Gonzalez C, Nannola N, Robesti D, Folcia A, Chicaud M, Kutchukian S, Candela L, Laurent B, Ventimiglia E, Montorsi F, Briganti A, Salonia A, Villa L, Doizi S, Traxer O, Panthier F. Zorzi F, et al. Among authors: robesti d. Cancers (Basel). 2026 Mar 3;18(5):821. doi: 10.3390/cancers18050821. Cancers (Basel). 2026. PMID: 41827753 Free PMC article. Review.
Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211.
Fallara G, Belladelli F, Robesti D, Malavaud B, Tholomier C, Mokkapati S, Montorsi F, Dinney CP, Msaouel P, Martini A. Fallara G, et al. Among authors: robesti d. Urol Oncol. 2025 Mar;43(3):188.e9-188.e17. doi: 10.1016/j.urolonc.2024.12.267. Epub 2025 Jan 9. Urol Oncol. 2025. PMID: 39788823 Clinical Trial.
Ho: YAG and thulium fiber lasers exhibit comparable temperature distribution: an in vitro evaluation of thermal safety distances for endourological applications-section of EAU endourology.
Robesti D, Corsini C, Perri D, Kwok JL, Tsaturyan A, Nedbal C, Villa L, Fossati N, Gallina A, Kartalas Goumas I, Salonia A, Gauhar V, Somani BK, Traxer O, Saccomandi P, Ventimiglia E. Robesti D, et al. World J Urol. 2025 Jul 1;43(1):405. doi: 10.1007/s00345-025-05754-7. World J Urol. 2025. PMID: 40591001
The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy.
Gandaglia G, Bravi CA, Dell'Oglio P, Mazzone E, Fossati N, Scuderi S, Robesti D, Barletta F, Grillo L, Maclennan S, N'Dow J, Montorsi F, Briganti A. Gandaglia G, et al. Among authors: robesti d. Eur Urol. 2018 Jul;74(1):4-7. doi: 10.1016/j.eururo.2018.02.025. Epub 2018 Mar 12. Eur Urol. 2018. PMID: 29544735
Perioperative outcomes, environmental impact and economic implications of pelvic drain discontinuation in prostate cancer patients undergoing robot-assisted radical prostatectomy.
Scuderi S, Scilipoti P, Nocera L, Longoni M, Quarta L, Zaurito P, Barletta F, Pellegrino F, de Angelis M, Robesti D, Pellegrino A, Stabile A, Larcher A, Montorsi F, Briganti A, Gandaglia G. Scuderi S, et al. Among authors: robesti d. Urol Oncol. 2025 Apr;43(4):271.e1-271.e8. doi: 10.1016/j.urolonc.2024.11.022. Epub 2024 Dec 16. Urol Oncol. 2025. PMID: 39690076
Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A. Bravi CA, et al. Among authors: robesti d. Eur Urol. 2020 Nov;78(5):661-669. doi: 10.1016/j.eururo.2020.06.043. Epub 2020 Jul 2. Eur Urol. 2020. PMID: 32624288 Free PMC article.
57 results